ClinicalTrials.gg
CompletedNCT01986361Updated Sep 28, 2017Results posted

Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method

A Phase 3 interventional study of flurbiprofen and placebo in Acute Pharyngitis and Sore Throat, sponsored by Reckitt Benckiser LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-28.

Sponsored by Reckitt Benckiser LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Pharyngitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pharyngitis · United States.

Enrollment
27th of 35
122 · median 204
Started
2013
with 4 others
Phase 3
18 of 41
none open now
Registered
24th of 41
by date
Lead sponsor
3 of 41
Reckitt Benckiser LLC

Among the 41 studies in Pharyngitis with a site in United States, this one is the 27th largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 24th registered.

Pharyngitis

227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.

Browse Pharyngitis studies →

Open to participants now

4 of the 41 studies in Pharyngitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Pharyngitis studies recruiting now, 5 (26%) set no upper age limit and 10 (53%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Pharyngitis with a site in United States, or all of them as a file.
02

Study summary

The study's purpose is to demonstrate the onset of action, i.e., time to meaningful pain relief in patients with pharyngitis, of flurbiprofen 8.75 mg lozenge using the Double-Stopwatch Method (DSW).

03

Conditions studied

  • Acute Pharyngitis
  • Sore Throat

Browse trials for

Keywords

  • Pharyngitis
  • Sore Throat
  • acute upper respiratory tract infection (URTI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis: pharyngitis confirmed by a Tonsillo-Pharyngitis Assessment ≥ 5
  • Complaint of sore throat with an onset ≤ 4 days prior to randomization
  • Have at least one symptom of upper respiratory tract infection (URTI) on the URTI Questionnaire (e.g., sore throat, runny nose, cough, fever)
  • Have moderate or severe sore throat pain on the Throat Pain Scale
  • Have a baseline Sore Throat Scale (STS) ≥ 6
  • If the patient is a female of , she has been using effective since the last date of menses and is not breast-feeding or lactating. She is also willing to take adequate contraceptive precautions through 24 hours after the completion of the study.
  • If the patient is a female of childbearing potential, the patient must have a negative urine pregnancy test (UPT) result (indicating "not pregnant") obtained on the day of scheduled randomization, prior to the designated time of randomization
  • The patient is willing to remain at the study centre for 3 hours after receiving the dose of study medication
  • During the 3-hour evaluation of the study medication lozenge at the site, the patient is willing to take "nothing by mouth" (e.g., no smoking, food, candy, lozenges, chewing gum, liquids).

Exclusion criteria

Exclusion Criteria:

  • Known allergy and/or to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), or any other inactive ingredients such as honey, lemon flavor, menthol, or sucrose.
  • History of an upper gastrointestinal ulcer within the past 60 days, current upper gastrointestinal complaints, or current regular use (≥ 3 times in the previous week) of any medication for upper gastrointestinal symptoms, including antacids, H2 blockers, proton pump inhibitors or sucralfate
  • History of any hepatic disease or renal dysfunction
  • Other severe acute or chronic medical condition that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
  • History of chronic analgesic use (≥ 3 times per week over the prior 4 weeks)
  • Use of an antibiotic for an acute disease within the previous 24 hours before randomization. (Chronic antibiotic use, such as for acne, is acceptable.) Use of any quinolone antibiotic such as ciprofloxacin or nalidixic acid within the past week or concurrently is specifically prohibited.
  • Use of mifepristone in the 12 days prior to the screening visit
  • Use of inhaled therapy (e.g., inhaled or β-agonists, such as Ventolin) on an acute basis for disease exacerbation in the week prior to the screening visit
  • Use of any immediate release analgesic within 4 hours preceding administration of the study medication.
  • Use of any sustained release analgesic within 12 hours preceding administration of the study medication.
  • Use of any "cold medication" (i.e. decongestants, antihistamines, expectorants, antitussives) within 4 hours preceding administration of the dose of study medication.
  • Use of any throat lozenge, throat spray, cough drop, or menthol-containing product within 2 hours preceding administration of the study medication
  • Consumption of any caffeine-containing beverage (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) within 5 minutes preceding administration of the study medication.
  • Any evidence of mouth-breathing (which could worsen sore throat pain).
  • Coughing that causes throat discomfort or any active physical disease (such as bronchopneumonia) which could compromise respiratory function and worsen a sore throat
  • Unable in the opinion of the Investigator to comply fully with the study requirements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    flurbiprofen 8.75 mg lozenge

    A single flurbiprofen lozenge is sucked until fully dissolved.

    Drug: flurbiprofen

  • Placebo comparator
    Placebo lozenge

    A single placebo lozenge is sucked until fully dissolved.

    Drug: placebo

Interventions

  • A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.

  • Drugplacebo

    A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.

06

What researchers measure

Primary outcomes

  1. Kaplan-Meier Estimates for Time to Meaningful Pain Relief

    Time to meaningful pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the second stop watch when they experience what they perceive as meaningful pain relief. Instructions to participants are: "Stop the second stopwatch when the sore throat pain relief is meaningful to you. This does not mean you feel completely better, although you might, but when you feel relief of throat pain that is meaningful to you." Participants who did not have perceived pain relief were censored at 3 hours.

    Time frame: up to 3 hours post dose on Day 1

Secondary outcomes

  1. Kaplan-Meier Estimates for Time of First Perceived Pain Relief

    Time to first perceived pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the first stop watch when they experience any pain relief, termed "perceived pain relief". Instructions to participants are: "Stop the first stopwatch when you first feel any sore throat pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief of the throat pain you have now." Participants who did not have perceived pain relief were censored at 3 hours.

    Time frame: up to 3 hours post dose on Day 1

  2. Kaplan-Meier Estimates for Time to First Perceived Pain Relief That Is Confirmed By Meaningful Pain Relief

    Time to first perceived pain relief on the first stopwatch that was confirmed by meaningful pain relief on the second stopwatch. Participants who had no meaningful pain relief within 3 hours from baseline were censored to 3 hours.

    Time frame: up to 3 hours post dose on Day 1

  3. Kaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS)

    Time to first indication of sore throat relief, defined as any reduction or decrease in STS observed during the 3 hours post dose. Participants who did not have any reduction in STS from baseline within 3 hours were censored to 3 hours. The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.

    Time frame: up to 3 hours post dose on Day 1

  4. Kaplan-Meier Estimates for Time of First Perceived Pain Reduction on the Sore Throat Scale (STS) Which is Followed by ≥ 20% Pain Reduction on the Sore Throat Pain Intensity Scale (STPIS)

    Time to pain reduction on the STS (defined as any reduction or decrease observed during the 3 hours post dose) for participants whose improvement was confirmed by a \>=20% reduction in pain on the STPIS. STS: The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours. STPIS: The participant was instructed to swallow and: "Place a line on the Sore Throat Scale that best characterizes the severity of your sore throat now:" 0mm=no pain and 100mm=severe pain. The STPIS was obtained at baseline, after the participant depressed the second stopwatch, and at 1, 2, and 3 hours postdose.

    Time frame: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1

  5. Change From Baseline at Individual Timepoints in Sore Throat Scale (STS)

    The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.

    Time frame: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1

  6. Percentage of Participants With Meaningful Pain Relief

    Defined as the percentage of participants who pressed the second stopwatch during the 3 hour evaluation period.

    Time frame: up to 3 hours post dose on Day 1

  7. Percentage of Participants With Perceived Pain Relief

    Defined as the percentage of participants who pressed the first stopwatch during the 3 hour evaluation period.

    Time frame: up to 3 hours post dose on Day 1

  8. Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Scale (STS) Over the 3 Hours Post-baseline (STS SPID3)

    The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours, for a total of 24 post-dose measurements. The time-weighted SPID combines relief magnitude (PID = change from baseline) as weighted by duration interval between ratings. SPID3 refers to measurements taken up to 3 hours post-baseline, and has a full range of -1332 (complete pain relief within 5 minutes of dosing that lasts for 3 hours) to 468 (drug escalates level of pain to a score of 10 and the pain stays at that level for 3 hours) using the mean baseline STS value 7.4 for this study.

    Time frame: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1

07

Results

Posted Aug 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Started10121
Completed10121
Not completed00

Outcome measures

PrimaryKaplan-Meier Estimates for Time to Meaningful Pain Relief

Time to meaningful pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the second stop watch when they experience what they perceive as meaningful pain relief. Instructions to participants are: "Stop the second stopwatch when the sore throat pain relief is meaningful to you. This does not mean you feel completely better, although you might, but when you feel relief of throat pain that is meaningful to you." Participants who did not have perceived pain relief were censored at 3 hours.

Time frame:
up to 3 hours post dose on Day 1
Reported as:
Median · minutes
Kaplan-Meier Estimates for Time to Meaningful Pain Relief
minutesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Kaplan-Meier Estimates for Time to Meaningful Pain Relief42.917 (36.367 to 49.383)NA (47.567 to NA)
SecondaryKaplan-Meier Estimates for Time of First Perceived Pain Relief

Time to first perceived pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the first stop watch when they experience any pain relief, termed "perceived pain relief". Instructions to participants are: "Stop the first stopwatch when you first feel any sore throat pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief of the throat pain you have now." Participants who did not have perceived pain relief were censored at 3 hours.

Time frame:
up to 3 hours post dose on Day 1
Reported as:
Median · minutes
Kaplan-Meier Estimates for Time of First Perceived Pain Relief
minutesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Kaplan-Meier Estimates for Time of First Perceived Pain Relief10.867 (7.633 to 14.283)19.317 (4.783 to 30.333)
SecondaryKaplan-Meier Estimates for Time to First Perceived Pain Relief That Is Confirmed By Meaningful Pain Relief

Time to first perceived pain relief on the first stopwatch that was confirmed by meaningful pain relief on the second stopwatch. Participants who had no meaningful pain relief within 3 hours from baseline were censored to 3 hours.

Time frame:
up to 3 hours post dose on Day 1
Reported as:
Median · minutes
Kaplan-Meier Estimates for Time to First Perceived Pain Relief That Is Confirmed By Meaningful Pain Relief
minutesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Kaplan-Meier Estimates for Time to First Perceived Pain Relief That Is Confirmed By Meaningful Pain Relief13.200 (8.633 to 16.567)NA (6.633 to NA)
SecondaryKaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS)

Time to first indication of sore throat relief, defined as any reduction or decrease in STS observed during the 3 hours post dose. Participants who did not have any reduction in STS from baseline within 3 hours were censored to 3 hours. The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.

Time frame:
up to 3 hours post dose on Day 1
Reported as:
Median · minutes
Kaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS)
minutesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Kaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS)15.000 (10.000 to 15.000)20.000 (5.000 to 30.000)
SecondaryKaplan-Meier Estimates for Time of First Perceived Pain Reduction on the Sore Throat Scale (STS) Which is Followed by ≥ 20% Pain Reduction on the Sore Throat Pain Intensity Scale (STPIS)

Time to pain reduction on the STS (defined as any reduction or decrease observed during the 3 hours post dose) for participants whose improvement was confirmed by a \>=20% reduction in pain on the STPIS. STS: The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours. STPIS: The participant was instructed to swallow and: "Place a line on the Sore Throat Scale that best characterizes the severity of your sore throat now:" 0mm=no pain and 100mm=severe pain. The STPIS was obtained at baseline, after the participant depressed the second stopwatch, and at 1, 2, and 3 hours postdose.

Time frame:
Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Reported as:
Median · minutes
Kaplan-Meier Estimates for Time of First Perceived Pain Reduction on the Sore Throat Scale (STS) Which is Followed by ≥ 20% Pain Reduction on the Sore Throat Pain Intensity Scale (STPIS)
minutesFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Kaplan-Meier Estimates for Time of First Perceived Pain Reduction on the Sore Throat Scale (STS) Which is Followed by ≥ 20% Pain Reduction on the Sore Throat Pain Intensity Scale (STPIS)15.000 (10.000 to 20.000)NA (10.000 to NA)
SecondaryChange From Baseline at Individual Timepoints in Sore Throat Scale (STS)

The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.

Time frame:
Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Reported as:
Mean · units on a scale
Change From Baseline at Individual Timepoints in Sore Throat Scale (STS)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Minute 5-0.4 ± 0.90-0.4 ± 0.67
Minute 10-0.7 ± 1.14-0.6 ± 0.98
Minute 15-0.9 ± 1.26-0.6 ± 0.87
Minute 20-1.0 ± 1.30-0.6 ± 0.74
Minute 25-1.3 ± 1.34-0.7 ± 0.90
Minute 30-1.6 ± 1.41-1.0 ± 1.12
Minute 35-1.8 ± 1.52-1.0 ± 1.20
Minute 40-2.0 ± 1.50-1.1 ± 1.34
Minute 45-2.2 ± 1.54-1.2 ± 1.36
Minute 50-2.3 ± 1.59-1.3 ± 1.52
Minute 55-2.4 ± 1.64-1.1 ± 1.49
Minute 60-2.5 ± 1.69-1.1 ± 1.65
Minute 70-2.6 ± 1.74-1.2 ± 1.72
Minute 80-2.7 ± 1.85-1.1 ± 1.61
Minute 90-2.7 ± 1.86-1.0 ± 1.77
Minute 100-2.7 ± 1.87-1.0 ± 1.72
Minute 110-2.7 ± 1.85-1.0 ± 1.83
Minute 120-2.7 ± 1.91-1.0 ± 1.94
Minute 130-2.6 ± 1.86-1.0 ± 1.83
Minute 140-2.6 ± 1.95-0.9 ± 1.82
Minute 150-2.5 ± 1.99-0.8 ± 1.97
Minute 160-2.4 ± 2.01-0.9 ± 2.06
Minute 170-2.3 ± 2.06-0.8 ± 2.23
Minute 180-2.3 ± 2.05-0.8 ± 2.06
SecondaryPercentage of Participants With Meaningful Pain Relief

Defined as the percentage of participants who pressed the second stopwatch during the 3 hour evaluation period.

Time frame:
up to 3 hours post dose on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Meaningful Pain Relief
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Percentage of Participants With Meaningful Pain Relief78.2 (70.2 to 86.3)47.6 (26.3 to 69.0)
SecondaryPercentage of Participants With Perceived Pain Relief

Defined as the percentage of participants who pressed the first stopwatch during the 3 hour evaluation period.

Time frame:
up to 3 hours post dose on Day 1
Reported as:
Number · percentage of participants
Percentage of Participants With Perceived Pain Relief
percentage of participantsFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Percentage of Participants With Perceived Pain Relief97.0 (93.7 to 100.0)76.2 (58.0 to 94.4)
SecondaryTime Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Scale (STS) Over the 3 Hours Post-baseline (STS SPID3)

The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours, for a total of 24 post-dose measurements. The time-weighted SPID combines relief magnitude (PID = change from baseline) as weighted by duration interval between ratings. SPID3 refers to measurements taken up to 3 hours post-baseline, and has a full range of -1332 (complete pain relief within 5 minutes of dosing that lasts for 3 hours) to 468 (drug escalates level of pain to a score of 10 and the pain stays at that level for 3 hours) using the mean baseline STS value 7.4 for this study.

Time frame:
Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Reported as:
Mean · units on a scale
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Scale (STS) Over the 3 Hours Post-baseline (STS SPID3)
units on a scaleFlurbiprofen 8.75 mg LozengePlacebo Lozenge
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Scale (STS) Over the 3 Hours Post-baseline (STS SPID3)-403.9 (-457.3 to -350.5)-166.4 (-286.8 to -46.0)

Adverse events

Collected over up to 20 hours post dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Flurbiprofen 8.75 mg Lozenge—0/101 (0%)10/101 (9.9%)
Placebo Lozenge—0/21 (0%)1/21 (4.8%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventFlurbiprofen 8.75 mg LozengePlacebo Lozenge
HeadacheNervous system disorders1/1011/21
NauseaGastrointestinal disorders2/1010/21
PyrexiaGeneral disorders2/1010/21
Abdominal discomfortGastrointestinal disorders1/1010/21
DiarrhoeaGastrointestinal disorders1/1010/21
DizzinessNervous system disorders1/1010/21
CoughRespiratory, thoracic and mediastinal disorders1/1010/21
Throat irritationRespiratory, thoracic and mediastinal disorders1/1010/21
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders1/1010/21
Conjunctivitis infectiveInfections and infestations1/1010/21

Baseline characteristics

Randomized

Age, Continuous
Age, Continuous(years)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean19.5 ± 2.0219.6 ± 1.3619.5 ± 1.92
Sex: Female, Male
Sex: Female, Male(Participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Female581371
Male43851
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Hispanic or Latino8210
Non-Hispanic or Non-Latino9319112
Primary Race
Primary Race(Participants)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Asian202
Black or African American325
Multi-Racial202
White9419113
Weight
Weight(pounds)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean154.09 ± 31.221154.19 ± 35.885154.11 ± 31.913
Height
Height(inches)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean67.67 ± 4.18766.90 ± 3.69767.54 ± 4.103
Sore Throat Scale (STS) Score
Sore Throat Scale (STS) Score(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean7.4 ± 0.977.3 ± 1.027.4 ± 0.98
Sore Throat Pain Intensity Scale (STPIS)
Sore Throat Pain Intensity Scale (STPIS)(units on a scale)Flurbiprofen 8.75 mg LozengePlacebo LozengeTotal
Mean73.8 ± 9.7873.8 ± 9.6473.8 ± 9.71
08

Study locations

1 site
  • University of Connecticut - Student Health Services
    Storrs, Connecticut 06269-4011, United States
09

References and documents

Publications

  • Schachtel B, Shephard A, Schachtel E, Lorton MB, Shea T, Aspley S. Qualities of Sore Throat Index (QuaSTI): measuring descriptors of sore throat in a randomized, placebo-controlled trial. Pain Manag. 2018 Mar;8(2):85-94. doi: 10.2217/pmt-2017-0041. Epub 2018 Jan 30. PubMed 29381110 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Nov 18, 2013
Start
Sep 2013
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Aug 24, 2017
Last update
Sep 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986361
Responsible party
Sponsor
First posted
Nov 18, 2013
Start date
Sep 2013
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Aug 24, 2017
Last update
Sep 28, 2017

Study contacts

Timothy Shea, BS
study director · Reckitt Benckiser Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flurbiprofen

Start the discussion